The rise of antibody-drug conjugates in cancer therapy Antibody-drug conjugates (ADCs) are a growing class of cancer therapies that use targeted antibodies to deliver chemotherapy directly to cancer cells, minimizing damage to healthy tissue. After years of development, major pharma companies are investing heavily in ADCs, though the technology faces both successes and setbacks across different treatment settings. INCLUDED IN THIS TRENDLINE Merck makes case for a ‘cornerstone’ cancer drug Pfizer drug acquired in Seagen deal disappoints in lung cancer study J&J acquires Firefly, maker of ‘degrader’ antibody drugs, for $1B
